Ambrx Inc., a San Diego, CA-based clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, closed a US$200m crossover financing round.
Backers included new investors Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management.
Led by Dr. Feng Tian, CEO and Chairman, Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code to create Precision Biologics, this includes next-generation antibody-drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as novel cytokines to modulate the immune system and long-acting therapeutic peptides for metabolic and cardiovascular disease, all designed to have improved pharmacologic properties and novel biological activity.
The company is advancing a portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use in multiple therapeutic areas. Ambrx has collaborations with Bristol-Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and ZMC, with drug products generated using Ambrx technology in different stages of clinical trials.